From: chemistry-request at ccl.net <br />
To: chemistry-request at ccl.net<br />
Date: Sat Mar  4 11:45:19 2006<br />
Subject: 06.09.10 <span class="fancysmall">ACS Meeting, Symposium on Estrogen Receptor Ligand Binding Domain (LBD), San Francisco, CA</span><br />

<pre>Venue : 232nd National Fall ACS Meeting, San Francisco, CA
Dates : September 10th - 14th, 2006
Sponsored by : COMP Division


 Ligand-dependent activation and inactivation of transcription by nuclear hormone
 receptors are mediated by the recruitment of co-activators and/or co-repressors
 by the receptor. Receptor agonists promote co-activator binding while
 antagonists block co-activator binding or promote co-repressor binding thereby
 affecting transcriptional activity. At a molecular level, in the estrogen
 receptor, these mechanistic events have been explained to an extent by the
 solution of several estrogen receptor ligand binding domain (LBD) agonist and
 antagonist crystal structures.
 In the diethylstilbestrol (DES) agonist complex structure, the co-activator
 peptide binds to a hydrophobic groove on the surface of the LBD, which is
 promoted by a conformation of the LBD where the helix 12 is tucked over the
 binding pocket. In the 4-hydroxytamoxifen (OHT) antagonist structure, the side
 chain of OHT projects out of the ligand binding pocket, which promotes a
 conformation of the LBD that results in helix 12 blocking the coactivator
 recognition groove. However, ligands that are smaller in size (that do not have
 the OHT sidechain) also vary in functional activities as reported by results
 from several recent publications. Investigations into ER-subtype selective
 modulators (alpha vs beta) using structure-based methods have also been
 described in the literature.
 We plan to organize a mini-symposium that would bring together a diverse group
 of researchers and scientists at the 232nd National Fall ACS Meeting, San
 Francisco, CA, who have thought about and applied structure-based methods to the
 evaluation and development of selective and/or non-selective estrogen receptor
 modulators as well as selective and/or non-selective estrogen receptor subtype
 modulators. This symposium will be sponsored by the COMP division of the
 American Chemical Society.
 Symposium: Structure-Based Design & Development of Estrogen Receptor
 Modulators
 Venue : 232nd National Fall ACS Meeting, San Francisco, CA
 Dates : September 10th - 14th, 2006
 Sponsored by : COMP Division
 Co-chairs : Veer Shanmugasundaram & Neil Raheja, Pfizer Global Research
 & Development, Ann Arbor, MI
 Please submit your abstracts for this symposium using OASYS 
 <a href="http://oasys.acs.org/acs/232nm/comp/papers/index.cgi" target="_blank">http://oasys.acs.org/acs/232nm/comp/papers/index.cgi</a>
 The deadline for submitting abstracts is April 25, 2006.
 Thank you,
 Veer.
 ----
 Veer Shanmugasundaram, Ph.D
 Computer-Assisted Drug Discovery,
 Pfizer Global Research & Development,
 2800 Plymouth Road,
 Ann Arbor, MI 48105.
 Tel:(734)622-7131
 Fax:(734)622-2782
 Email:Veerabahu.Shanmugasundaram[#]pfizer.com
 Neil Raheja, Ph.D
 Medicinal Chemistry,
 Pfizer Global Research & Development
 Ann Arbor, MI 48105
 Tel: (734)622-2305
 Fax:(734)622-3107
 Email: Neil.Raheja[#]pfizer.com</pre>
</PRE>
<B>NOTE THAT E-MAIL ADDRESSES HAVE BEEN MODIFIED!!!</B><br />
All @ signs were changed to *|* to fight spam. Before you send e-mail, you
need to change *|* to @<br />
For example: change joe*|*big123comp.com to joe@big123comp.com<br />
<em>Please let colleagues know about conference listingts at
Computational Chemistry List Conference Page at</em>
<a href="http://www.ccl.net/chemistry/a/conferences/"
class="link">http://www.ccl.net/chemistry/a/conferences/</a>.